Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV: ATE) is proud to announce that Dr. John Wallace, the Corporation's Founder and Chief Science Officer, was awarded the Heymans Foundation Memorial Medal in Ghent, Belgium, today. This prestigious award, named after Corneille Heymans, a 1938 Nobel Prize winner for Physiology/Medicine, has only been awarded 10 times since being established in 1972. Six of the previous winners were Nobel Laureates.
Dr. Wallace received this honour based on his studies of hydrogen sulfide as an endogenous anti-inflammatory, as well as the development of new medicines based on those findings, through Antibe Therapeutics.
For the last 20 years, Dr. Wallace's research has focused on gaining a better understanding of the ulcers that can arise from using painkillers and arthritis medications as well as of some the most common digestive disorders, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, and colon cancer.
Study suggests high levels of vitamin B3 breakdown products are linked to higher risk of mortality, heart attacks, and stroke